What is the Prognostic Value of HALP Score, Monocytopenia, Hypofibrinogenemia, and AST/ALT Ratio in Patients With Myelodysplastic Syndromes

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University

About this trial

to investigate prognostic significance of many factors in MDS including HALP score ( haemoglobin level, albumin level, lymphocyte, platelets), monocytopenia, hyperfibrinogenemia and AST/ALT ratio in patients with MDS at Assiut University Hospital.

And to study overall survival and leukemia free survival rates in MDS patients.

Eligibility criteria

Qualifiers

• Adults (≥18 years old) diagnosed with MDS according to WHO criteria

Availability of complete medical records including laboratory data for hemoglobin, albumin, lymphocyte count, platelet count, monocyte count, fibrinogen level, AST and ALT

Patients who were followed for at least 12 months post-diagnosis or until death

Disqualifiers

Patients with active infections, liver cirrhosis, chronic inflammatory diseases, or concurrent malignancies at time of diagnosis

Incomplete laboratory or clinical data

Patients lost to follow-up within less than 3 months of diagnosis

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

This trial has no locations

Sponsors and collaborators